柳叶刀机器人 z-bio 2025-07-03 2521

　　Artery Network learned at the first time that Shenzhen Lancet Robot Co., Ltd. ("Lancet Robot"), a domestic innovative medical device company for surgical robots, announced that it had completed a round of A+ financing of tens of millions of yuan, and this round of financing was invested by Yuehu Fund. This is another round of financing completed by the Lancet Robot after half a year. This round of funds will be focused on the industrialization base of domestic surgical robots across departments, subsequent product research and development iteration and global commercial layout, further consolidating the company's innovative leading position in the field of domestic surgical robots.

　　01 Multi-dimensional AI empowerment, cross-department surgical robot clinical application leads new standards for precision surgery

　　Lancet Robot focuses on creating a comprehensive full-process solution for artificial intelligence surgical robots for medical institutions. After years of technological precipitation and market expansion, Lancet Robot has successfully built a complete set of surgical robot products and service systems, covering multiple key clinical departments and fields such as joint replacement, spinal trauma, oral implantation, neurosurgery, and vascular intervention. Up to now, the company has obtained 5 Class III medical device registration certificates, 1 US FDA510 (K) registration certificate, and 2 Class II medical device registration certificates, and has won many national and provincial awards and honors, with a total of nearly 400 intellectual property rights, including 166 invention patents. In addition, a number of cross-department surgical robot products such as minimally invasive tumor intervention and neurosurgery are steadily advancing the NMPA and FDA registration process, further demonstrating the firm determination and strong strength of the Lancet robot to take clinical pain points as the innovative origin and continue to transform the Chinese solution of cross-department surgical robots.

　　02 The core components are fully domesticized, helping to cover general medical coverage of surgical robots

　　With its strong independent research and development capabilities, the Lancet robot has continuously broken through core technologies and successfully achieved 100% domestic production of surgical robots from key algorithms, mass production processes to core components. This has greatly reduced the production and terminal prices of surgical robots, effectively cracked the price barriers of high-end medical equipment, and promoted the process of comprehensive domestic replacement of high-end surgical robots. Through cost-effective intelligent equipment, high-quality medical services can benefit more patients. This measure not only promotes the widespread application of surgical robots in high-end Grade A hospitals, but also allows them to go deep into grassroots public hospitals and private medical institutions in prefectures, districts and counties, significantly improving the surgical technical level and service capabilities of primary medical institutions. At present, the products of Lancet robots have been put into use in dozens of hospitals, making robot-assisted surgery within reach in grassroots hospitals, breaking the situation where high-end equipment only serves a few patients, providing strong support for the balanced development of medical resources, and promoting the transformation of robot-assisted surgery from "concentration of a few hospitals" to "popularization of hospitals at all levels", truly realizing the universal coverage of high-end technologies.

　　03 Layout overseas emerging markets and build a new paradigm for surgical robots to go overseas

　　In the context of the global surgical robot market being monopolized by international giants, Lancet Robots, with the dual-wheel drive strategy of "FDA certification + emerging markets", is the first domestic surgical robot company to win the US FDA510 (K) of joint replacement surgical robots. Through continuous breakthroughs in technology, Lancet Robots drive overseas market development, focus on emerging markets with scarce medical resources, and take the lead in building the overseas paradigm of intelligent joint replacement surgical robots in China.The company has made arrangements in strategic regions such as Southeast Asia, South Asia, and South America to accurately capture the local medical intelligent upgrade needs. It has now obtained more than 20 overseas orders and has completed multiple robot-assisted surgeries in overseas clinical centers, providing the industry with a highly reference value for global development samples.

　　Mr. Huang Zhijun, Chairman of the Lancet Robot, said: Thank you to Yuehu Fund for its high recognition and support for the Lancet Robot.In just a few years, the company has broken through key technologies that can be bored through independent research and development, and has achieved 100% domestic production of core components of surgical robots, successfully breaking the technology monopoly and commercial structure of imported products.The Lancet Robot will take this round of financing as an opportunity to accelerate the registration and listing of a number of cross-department domestic surgical robots and the expansion of indications with the innovative system of medical and industrial integration and the ability to research and develop medical and industrial technology, actively promote the subsidy of domestic surgical robots to primary care, empower a wider range of grassroots hospitals and patients with intelligent equipment, and actively expand overseas global layout.We believe that this financing will help Lancet robot accelerate the research and development of new products, expand production capacity and commercialization, accelerate it to become an industry benchmark, continue to promote the intelligent development of medical surgical equipment, provide better and more advanced medical services to the majority of patients, and inject Chinese strength into the global smart medical industry.

　　Yuehu Fund said: I am very happy to participate in this round of investment in Lancet Robot.Under the technical difficulties of the academician team, the Lancet robot has achieved a "dual breakthrough" between the domestic NMPA and the US FDA in the field of hip and knee replacement robots. The 96.6% acetabular installation accuracy of RobPath-THA robot has even set a new industry standard.Its non-closed platform design breaks down technical barriers, and the business closed-loop model of "equipment + consumables + service" deeply integrates excellent technical strength with the people's livelihood sentiment of "technology inclusive", providing a new paradigm for the development of medical technology.

　　About the Lancet Robot

　　The Lancet Robot was founded in 2018. It is a specialized and specialized enterprise in Zhejiang Province that deeply lays out the four major golden surgical tracks of spinal/trauma, joint replacement, oral implantation and vascular intervention.Most of the core members of the R&D team graduated from science and engineering and clinical medicine majors in well-known universities at home and abroad. They have a strong background in integrating medical and engineering and solid technical strength. They have also established a stable and efficient scientific research innovation platform integrating production, academic, research and medicine with Gulou Hospital Affiliated to Nanjing University School of Medicine and the Second Affiliated to Zhejiang University.The company is committed to providing hospitals